Stephen Twomey Publishes New Resource Exploring Private Equity Fund Platforms and Access to Private Markets

Garfield Township, Michigan - February 25, 2026 - PRESSADVANTAGE - Stephen Twomey has published a new educational ...

Haleon H2 Earnings Call Highlights

Haleon (NYSE:HLN) executives fielded questions from analysts following the company’s fiscal year 2025 results, focusing on the outlook for organic sales growth, the impact of a soft cold and flu ...

Eco Wave Power Highlighted in U.S. Department of Energy National Laboratory Report Emphasizing the Strong Economic and Deployment Advantages of Coastal S…

Eco Wave Power Global AB (NASDAQ: WAVE) ("Eco Wave Power" or the "Company"), a leading developer of onshore wave energy ...

Press Advantage Addresses Growing Brand Displacement Risk as AI Transforms Search Results

Las Vegas, NV - February 18, 2026 - PRESSADVANTAGE - Press Advantage, a leading press release distribution service, is ...

Scientel Announces Gensonix AI LLM For Intel ARC Series GPUs

Gensonix AI DB efficiency combined with Intel's ARC GPU architecture makes LLMs practical on very small systems We are ...

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

BofA Retains a Neutral rating on Arm Holdings plc (ARM)

Arm Holdings plc (NASDAQ:ARM) is among the Most Volatile Stocks. On 9, 2026, BofA increased Arm Holdings plc (NASDAQ:ARM) ...

Industrial Coatings Market Size to Surpass USD 176.06 Billion by 2035

The global Industrial Coatings market size was valued at USD 117.13 billion in 2025 and is expected to hit around USD 176.06 ...

Hume Band 2026 Consumer Report: What Hume Health Discloses About "Metabolic Momentum," Biological Age Metrics, and Longevity Tracking

An informational overview examining category context, publicly available product disclosures, and what consumers often ...

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. F ...